Swedish biopharmaceutical company Calliditas Therapeutics signed and fully drew on a term loan of €92 million ($102.3 million) with funds managed by Athyrium Capital Management.
BlackRock and Kreos Capital entered into a definitive agreement under which BlackRock will acquire full control of Kreos, which is a provider of growth and venture debt financing to companies in the technology and healthcare industries.
Motus GI Holdings refinanced its debt and expanded its long-term credit facility with a new loan agreement with Kreos Capital for up to $12 million. The new facility replaces Motus GI Holdings’ previous term loan agreement with Silicon Valley Bank and removes an existing $10 million minimum cash balance liquidity covenant.
Nexstim, a medical technology company, entered into a €4 million ($4.717 million) loan agreement with growth debt financer Kreos Capital.
Dutch pharmaceutical firm Pharming Group replaced its $100 million bridge finance with a $100 million permanent facility agreement. OrbiMed provided both financings.